The Only End-to-End Forum Solely Dedicated to Targeting Inflammatory/Regenerative Pathways Whilst Overcoming Challenges With Drug Delivery, Safety and Validated Endpoints To Bring About Clinically Effective Dry-AMD Therapies
In the context of unprecedented Phase III progress, and as new investigational pharmacological agents enter the clinic, Dry-AMD Therapeutic Development returns for its 2nd year as the world’s definitive industry forum committed to delivering greater breadth and depth of technical content within the dry-AMD field than any other meeting.
As Lineage Cell Therapeutics’ OpRegen clinical data continues to demonstrate improvements in dry-AMD/GA, and LumiThera announce further positive interim data in visual and ERG clinical outcomes for dry-AMD, ensure you join them and 200+ ophthalmology experts as they unite under a common goal of accelerating the approval of next generation therapies for this high unmet medical disease.
Hear updates from next-generation complement clinical programs, strive to identify novel approaches targeting inflammasome inhibition and HtrA1 inhibitors, and navigate key challenges with the lack of predictable animal models, validated clinical meaningful endpoints and biomarkers.
Designed in combination with the leading dry-AMD therapeutic developers, this 3-day, two-track program will address a wide variety of today’s research and development approaches in the field, from small molecule interventions to advanced cell and gene therapy.
The agenda will include vital studies in the space targeting several disease mechanisms such as neuroprotection, reducing toxic by-product accumulation, visual cell modulation, and stem cells complement inhibition, along with providing insight into broader challenges for advancing therapeutic agents in this field.
To register for this event, go here.
To see the agenda, go here.